Advertisement

Topics

Latest Cancer NewsRSS

23:48 EDT 28th June 2017 | BioPortfolio

Cervical CancerMarket Insights, Epidemiology and Market Forecast2023 United States [Report Updated: 30052017] Prices from USD $2083

DelveInsight's Cervical Cancer Market Insights, Epidemiology and Market Forecast2023 United States Report provides marketed drugs information of Cervical Cancer. It includes historical and forecasted epidemiology and market size of the Cervical Cancer of US for 20132023.DelveInsight estimates that the market size of Cervical Cancer in United States is expected to grow at a Compound Annual Growth R...

Minomic Clinical Study Progresses For MiltuximabTM In Prostate, Bladder, and Pancreatic Cancer

Drug Safety Monitoring Committee Approval to Proceed to Final Six Patients of Twelve First-in-human trial on safety and tolerability passes key stage-gate Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-3...

Endometrial Cancer Epidemiology Forecast To 2023 [Report Updated: 31052017] Prices from USD $2338

DelveInsight Endometrial Cancer Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Endometrial Cancer in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Endometrial Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevaili...

The Natural Dentist Offers A $5 Rebate For People With Bleeding Gums!

MADISON, N.J., July 10, 2012 /PRNewswire/ --  The Natural Dentist, a line of therapeutic mouth rinses, announces a $5 rebate available through their website (www.bleedinggums.com). Continuing their 'No Pink in the Sink' campaign, The Natural Dentist makes an aggressive move to push consumers to treat bleeding gums, often the first sign of gingivitis. The Natural Dentist Healthy Gums™ ...

Breast Biopsy Market by Product [Vacuum Assisted Biopsy VAB, Core Needle Biopsy CNB and Fine Needle Aspiration Biopsy FNAB], Image Guided Technology MRIGuided Biopsy, Ultrasound Guided Biopsy, Mammography Guided Stereotactic Biopsy, CTGuided Biopsy and En

Breast biopsy is a preliminary test that detects the area of an abnormal tissue growth or diagnoses the presence of cancerous cells. Defects or abnormalities are detected in the cell with the help of devices, such as vacuumassisted biopsy, core needle biopsy, and fine needle biopsy. Moreover, assist the surgeons or radiologist performing the biopsy and using specialized imaging equipment, such as ...

MediPoint: Pancreatic and Biliary Stents Middle East and Africa Analysis and Market Forecasts [Report Updated: 01042017] Prices from USD $5000

MediPoint: Pancreatic and Biliary Stents Middle East and Africa Analysis and Market ForecastsSummaryThe pancreatic and biliary stents market is driven by two procedures: endoscopic retrograde cholangiopancreatography and percutaneous transhepatic cholangiography. There are four primary pancreatic and biliary stents; the covered metal stents, the partially covered metal stents, the noncovered meta...

3SBio Inc. Schedules Unaudited Second Quarter 2012 Results

SHENYANG, China, July 17, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited second quarter 2012 results on Wednesday,  August 15, 2012 at 8:00am China Standard Time. Following the earnings anno...

Hologic Human Papillomavirus (HPV) High-Risk Test Approved for Use in The Netherlands Population Cervical Screening Programme

BEDFORD, Mass., July 18, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the NVVP (Netherlands Society for Pathology) has approved the use of the Hologic Cervista HPV H...

Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia

SAN DIEGO, July 18, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, received notice of U.S. Patent 8,222,370, titled "Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof."  This is the first U.S. patent issued around this mutation, and is part of a family of filed patents for Trovagene around NPM. M...

Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that it has appointed Rainer Boehm, M.D. and Hervé Hoppenot to its Board of Directors. “We are...

Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates

CAMBRIDGE, Mass., July 31, 2012 /PRNewswire/ -- Mersana Therapeutics, Inc., a biopharmaceutical company developing its Fleximer®  antibody-drug  conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, announced today that it has closed a $27 million Series A-1 financing led by new investor New Enterprise Associates (NEA).  Participation in the round al...

Pamela W. Coleman, M.D., F.A.C.S., F.P.M.R.S., is recognized by Continental Who's Who

WASHINGTON, June 28, 2017 /PRNewswire/ -- Pamela W. Coleman, M.D., F.A.C.S., F.P.M.R.S., is recognized by Continental Who's Who as a Pinnacle Professional of the Year in the medical field. Dr. Coleman is Interim Chief of and an Associate Professor of Urology at Howard University Hospital (HUH) in Washington, D.C. She earned her Bachelors of Science in chemistry, with a minor in math, from Geor...

Carolyn S. Watts is recognized by Continental Who's Who

NASHVILLE, Tenn., June 28, 2017 /PRNewswire/ -- Carolyn S. Watts, M.S.N., R.N., CWON, is recognized by Continental Who's Who as a Pinnacle Lifetime Member in recognition of her outstanding contributions to the Nursing field.  Watts currently serves as a Clinical Nurse Specialist and Clinical Instructor at the School of Nursing at Vanderbilt University Medical Center, which specializ...

Protocol First Selected by the Leukemia & Lymphoma Society (LLS) for Beat AML Master Trial Initiative

BERKELEY, Calif., June 28, 2017 /PRNewswire/ -- Protocol First (P1), a software-as-a-service (SaaS) EDC data management company, founded April 2015 in Berkeley, California, has been selected by The Leukemia & Lymphoma Society (LLS) for the Beat AML® Master Trial Initiative, a clinical trial in acute myeloid leukemia. The Beat AML Master Trial is among the first cancer clinical trial...

Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Cad Software

SHELTON, Connecticut, July 30, 2012 /PRNewswire/ -- International medical technology company, Sectra  (NASDAQ OMX Stockholm: SECT B), announces an agreement with Merge Healthcare to distribute its CADstream[TM] Software, fully integrated with Sectra Breast Imaging PACS.      (Logo: http://photos.prnewswire.com/prnh/20120601/537255 ) This strategic agreem...

Physicians Realty Trust Announces $735.0 Million of Executed Purchase and Sale Agreements, Including the Pending Acquisition of the Baylor Charles A. Sammons Cancer Center

Acquisition Guidance for 2017 increased from a range of $800 Million to $1.0 Billion to a range of $1.2 Billion to $1.4 Billion Provides Estimates of Second Quarter Financial Impacts from Recent Events Physicians Realty Trust (NYSE: DOC) (the “Company,” the “Trust,” “we,” “our” and “us”), a self-managed healthcare real esta...

Medical Marijuana Inc. and Canipa Holdings Drive Dixie X and CanChew Gum Toward EU Marketing Approval And Clinical Development

SAN DIEGO, Aug. 1, 2012 /PRNewswire/ -- Medical Marijuana Inc. (OTC: MJNA), a leading hemp industry innovator, is pleased to provide an update on the efforts of Canipa Holdings in regards to European Union marketing approvals for MJNA Portfolio Products including the Dixie X Brand and CanChew gum.  Approval Process Canipa Holdings is currently working with European Health Authorities and t...

Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR® Hydrogel in Israel

The Chaim Sheba Medical Center now offers the hydrogel spacer to reduce side-effects during prostate cancer radiation therapy Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, today announced that the first patients have been...

Lung Cancer Video Library – First Line Combinations, Immunotherapy with Chemo

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses First Line Combinations, Immunotherapy with Chemotherapy.Related Posts:Why Give Adjuvant Chemotherapy

Salix Announces Filing Acceptance for PLENVU®* Next Generation Bowel Cleansing Preparation for Colonoscopies

BRIDGEWATER, N.J., June 28, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX AND TSX: VRX)  wholly owned subsidiary, Salix Pharmaceuticals, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal disorders, today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Applicat...

Young Cancer Patient to Enjoy Personalized Summer Camp

SPARTANBURG, S.C., June 28, 2017 /PRNewswire-USNewswire/ -- More than any other activity 15-year-old Tron Foster loves fishing. As a young cancer patient this affinity has grown over the last six years in part through his annual participation in Camp Victory, sponsored by The Children's Security Blanket (CSB), a Spartanburg, SC based nonprofit providing support for children battling cancer. T...

Will Your Sunglasses Protect You From Serious Eye Disease?

SAN FRANCISCO, June 28, 2017 /PRNewswire-USNewswire/ -- With summer in full swing, the days are longer, the sun hotter, and the threat from the sun's damaging ultraviolet rays, greater. Excess sun exposure can put you at risk of serious short-term and long-term eye problems. This is true for young and old, year-round. Prevention is simple. Wear sunglasses that block ultraviolet radi...

Elekta Technology at Work in 100 Percent of America's Top Cancer Hospitals

ATLANTA, Aug. 3, 2012 /PRNewswire/ -- U.S. News & World Report recently issued its annual list of America's best hospitals, including the country's top-ranked hospitals for cancer. All 50 of these cancer hospitals are users of Elekta solutions, which include advanced information management, treatment planning, brachytherapy and treatment delivery. "Consistently ranking among the best in ...

Colorectal CancerGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30052017] Prices from USD $1700

DelveInsight's Report, Colorectal CancerGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Colorectal Cancer Report is to understand the market and pipeline status of the drugs around the Colorectal Cancer to explor...

Aethlon Medical Announces Fiscal 2017 Results

SAN DIEGO, June 28, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal year ended March 31, 2017. On March 13, 2017, Aethlon disclosed that it had concluded an FDA-approved feasibility study of Hemopurifier® therapy, which demonstrated the safety of the medic...

Quick Search
Advertisement
 

review and buy Cancer market research data and corporate reports here